Metraipolis › archive › dc_e28c29ac7fa7

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for patients with previously untreated locally recurrent… — Europe PMC PMID:40918537

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40918537
DOI
10.3389/fphar.2025.1654177
License (as archived)
solo-consultazione
Archived
2026-11-10T10:07:53.459Z
SHA-256 of the archived text
e859907a0c3b8b0dfb7dc1bc104301279446ec8887aaaf2bb8643f5dd812b54f
Stable URL of this page
https://metraipolis.com/documento/dc_e28c29ac7fa7

How to cite

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for patients with previously untreated locally recurrent… — Europe PMC PMID:40918537 — Europe PMC (en), https://europepmc.org/article/MED/40918537 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e28c29ac7fa7 (Metraipolis archive dc_e28c29ac7fa7, sha256 e859907a0c3b8b0dfb7dc1bc104301279446ec8887aaaf2bb8643f5dd812b54f)
BibTeX
@misc{dce28c29ac7fa7,
  title = {Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for patients with previously untreated locally recurrent… — Europe PMC PMID:40918537},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40918537},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e28c29ac7fa7; sha256 e859907a0c3b8b0dfb7dc1bc104301279446ec8887aaaf2bb8643f5dd812b54f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40918537. Agents can read the archived copy with the MCP tool read_document.